{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:32:41Z","timestamp":1793338361153,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jacl.2023.09.016","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T06:37:15Z","timestamp":1696401435000},"page":"748-755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Prevalence of lipoprotein(a) measurement in patients with or at risk of cardiovascular disease"],"prefix":"10.1016","volume":"17","author":[{"given":"Gregory A.","family":"Panza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4390-905X","authenticated-orcid":false,"given":"Olivia","family":"Blazek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Saucier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio B.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jacl.2023.09.016_bib0001","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. a scientific statement from the national lipid association","volume":"13","author":"Wilson","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.jacl.2023.09.016_bib0002","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2023.09.016_bib0003","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the copenhagen city heart study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacl.2023.09.016_bib0004","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2023.09.016_bib0005","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease","volume":"63","author":"O'Donoghue","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2023.09.016_bib0006","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.jacl.2023.09.016_bib0007","first-page":"1129","article-title":"2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"issue":"25","key":"10.1016\/j.jacl.2023.09.016_bib0008","first-page":"e1046","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood Cholesterol: Executive summary: a report of the American college of Cardiology\/American heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jacl.2023.09.016_bib0009","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jacc.2021.01.051","article-title":"Emerging RNA therapeutics to lower blood levels of Lp(a): JACC focus seminar 2\/4","volume":"77","author":"Tsimikas","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2023.09.016_bib0010","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.jacl.2023.09.016_bib0011","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jacl.2020.06.010","article-title":"Lipoprotein(a) levels and association with myocardial infarction and stroke in a nationally representative cross-sectional US cohort","volume":"14","author":"Brandt","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"39","key":"10.1016\/j.jacl.2023.09.016_bib0012","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2023.09.016_bib0013","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1016\/j.jacl.2022.05.009","article-title":"Characterization of Lipoprotein(a) Measurement in a Large US Healthcare Dataset","author":"McGowan","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2023.09.016_bib0014","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.amjcard.2021.05.018","article-title":"Lipoprotein(a) testing patterns in a large health system","volume":"153","author":"Kelsey","year":"2021","journal-title":"Am J Cardiol"},{"issue":"14","key":"10.1016\/j.jacl.2023.09.016_bib0015","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1093\/eurjpc\/zwac124","article-title":"Lipoprotein(a) testing in clinical practice: real-life data from a large healthcare provider","volume":"29","author":"Zafrir","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2023.09.016_bib0016","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.atherosclerosis.2023.01.014","article-title":"Trends and consequences of lipoprotein(a) testing: Cross-sectional and longitudinal health insurance claims database analyses","volume":"367","author":"St\u00fcrzebecher","year":"2023","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.jacl.2023.09.016_bib0017","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jacl.2023.09.016_bib0018","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2023.09.016_bib0019","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.atherosclerosis.2023.04.012","article-title":"Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European atherosclerosis society","volume":"374","author":"Kronenberg","year":"2023","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.jacl.2023.09.016_bib0020","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jacc.2021.12.032","article-title":"Effect of Pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol","volume":"79","author":"Yeang","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.jacl.2023.09.016_bib0021","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287423002787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287423002787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:38:46Z","timestamp":1761831526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287423002787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1933287423002787"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2023.09.016","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of lipoprotein(a) measurement in patients with or at risk of cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2023.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 National Lipid Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}